Deucravacitinib in plaque psoriasis: a profile of its use
Funding The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest A. Lee is a salaried employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability not applicable.
Additional information about this Adis Drug Review can be found here.
Deucravacitinib (SOTYKTU™) is a tyrosine kinase 2 (TYK2) inhibitor that expands the availability of effective oral treatments for the management of moderate to severe plaque psoriasis in adults. In contrast to Janus kinase inhibitors that target Janus kinase 1–3, deucravacitinib selectively inhibits TYK2. This mechanism may allow more specific targeting of type-1 interferons and the interleukin (IL)-23/IL-17 pathway, which are associated with the pathophysiology of psoriasis. In two phase 3 clinical trials, deucravacitinib was superior to placebo in meeting coprimary efficacy endpoints at week 16. The efficacy of deucravacitinib was maintained in most patients who received treatment for 2 years. Deucravacitinib was generally well tolerated during the phase 3 trials and no new safety signals were reported after 2 years of treatment. Deucravacitinib was superior to apremilast with respect to almost all efficacy endpoints.
© Springer Nature Switzerland AG 2023